Drug Discovery 2026
WuXi AppTec is pleased to participate in ELRIG Drug Discovery 2026, taking place October 14–15, 2026, in London, United Kingdom. This year, our participation will focus on emerging oncology approaches including radiopharmaceuticals, bioconjugates, and other targeted therapeutic strategies.
Developing targeted oncology therapies requires close integration across chemistry, biology, pharmacology, and preclinical development. WuXi AppTec supports these programs through capabilities spanning medicinal chemistry, complex conjugate development, radiolabeling, oncology biology, in vitro and in vivo pharmacology, DMPK, bioanalysis, molecular imaging, biodistribution, and dosimetry. Our integrated platforms help partners characterize therapeutic candidates, evaluate target engagement and anti-tumor activity, understand distribution and exposure, and generate the data needed to advance promising oncology programs toward development.
Dr. Bin Liu and Dr. Zhongyao Ma will both present within the Targeted Potency: Advances in Radioligands and Bioconjugates track, sharing scientific perspectives on new approaches to targeted cancer therapy.
Visit WuXi AppTec at our connected 12 sqm exhibition space at Booths H03 and H10 to meet our scientists and learn how our integrated chemistry, biology, and preclinical capabilities can support radiopharmaceutical, bioconjugate, and broader oncology drug discovery programs.
To schedule a dedicated meeting with our team, please fill out the form on the right.
Resource Links
WuXi AppTec Biology Services
Resource Type: Brochure
Research Chemistry Services
Resource Type: Brochure
